Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of CLL. Blood 2008; 111: 5446–5456.

    Article  CAS  Google Scholar 

  2. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20: 504–511.

    Article  CAS  Google Scholar 

  3. Spaner DE, Foley R, Galipeau J, Bramson J . Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 2008; 27: 208–217.

    Article  CAS  Google Scholar 

  4. Shi Y, White D, He L, Miller RL, Spaner DE . TLR-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007; 67: 1823–1831.

    Article  CAS  Google Scholar 

  5. Spaner DE, Masellis A . TLR agonists in the treatment of CLL. Leukemia 2007; 21: 53–60.

    Article  CAS  Google Scholar 

  6. Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V et al. An exploratory study of systemic administration of the TLR-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14: 856–864.

    Article  CAS  Google Scholar 

  7. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S et al. First in human phase I trial of 852A, a novel systemic TLR-7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007; 13: 7119–7125.

    Article  CAS  Google Scholar 

  8. Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for CLL. J Clin Oncol 1991; 9: 770–776.

    Article  CAS  Google Scholar 

  9. Tomic J, White D, Shi Y, Mena J, Hammond C, He L et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176: 3830–3839.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from 3M Pharmaceuticals, Ontario Institute of Cancer Research (OICR) (#07Nov-61), Canadian Institutes of Health Research (CIHR) (MOP-79389) and the National Cancer Institute of Canada (NCIC), with funds from the Terry Fox Foundation (#018005) (to DS). We thank Drs Lisa Hicks for help with initial protocol development. This paper is dedicated to the memory of Dr Anna Masellis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D E Spaner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spaner, D., Shi, Y., White, D. et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24, 222–226 (2010). https://doi.org/10.1038/leu.2009.195

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.195

This article is cited by

Search

Quick links